Clopidogrel bisulfate is indicated for acute coronary syndrome, including unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI) and ST-elevation myocardial infarction (STEMI), as well as recent myocardial infarction, recent stroke, or established peripheral arterial disease.
Clinical Trial Data
The CURE study, involving 12,562 patients with ACS, demonstrated a 20% relative risk reduction in the primary outcome (cardiovascular death, MI, or stroke) with clopidogrel compared to placebo, with a loading dose of 300 mg followed by 75 mg daily in conjunction with aspirin. The benefit was maintained throughout the 12-month trial.
Pharmacological Action
It functions as a P2Y12 platelet inhibitor, irreversibly binding to platelet receptors and inhibiting ADP-mediated platelet aggregation. The active metabolite produced from clopidogrel is responsible for this action, affecting platelets for approximately 7 to 10 days. Inhibition of platelet aggregation was observed at 2 hours after a single oral dose, with steady-state inhibition between days 3 and 7 at a dose of 75 mg daily, averaging 40% to 60% inhibition.